Introduction: The Clinical Need for Integrated Joint Repair

Osteochondral defects represent one of the most challenging problems in orthopaedic medicine. These injuries involve damage to both articular cartilage and the underlying subchondral bone, creating a composite lesion that disrupts joint mechanics and causes pain, swelling, and progressive joint degeneration. Unlike simple cartilage lesions, osteochondral defects fail to heal spontaneously because cartilage is avascular and has limited regenerative capacity, while subchondral bone can form fibrocartilage that lacks the biomechanical properties of native hyaline cartilage. Over 30 million people in the United States alone suffer from osteoarthritis, and traumatic osteochondral injuries are common in young, active individuals. Current treatments, such as microfracture, autologous chondrocyte implantation (ACI), osteochondral autograft transplantation (OATS), and allograft procedures, are limited by donor site morbidity, graft availability, poor integration, and unpredictable long-term outcomes. The ultimate goal is to restore a functional osteochondral unit that mimics the native tissue architecture, and bioprinting has emerged as the most promising technology to accomplish this.

What Is a Osteochondral Unit?

The osteochondral unit is a highly organized, multi‐tissue structure that provides load‐bearing, lubrication, and shock absorption in diarthrodial joints. It comprises three distinct zones: the superficial cartilage layer, the deep calcified cartilage layer (the cement line), and the subchondral bone. The cartilage layer itself is stratified into superficial, middle, and deep zones, each with chondrocytes arranged in specific orientations and expressing different matrix components. The underlying subchondral bone provides mechanical support and contains blood vessels and marrow elements that are essential for nutrient exchange. Repairing this entire unit requires simultaneous regeneration of two very different tissue types: hyaline cartilage (which is predominantly type II collagen and proteoglycans) and bone (type I collagen, hydroxyapatite mineral), bonded together by an intermediate calcified cartilage interface. Traditional grafts often fail because they cannot replicate this gradation, leading to mechanical mismatch or delamination. Bioprinting offers a solution by building these zones layer by layer with controlled composition and architecture.

Bioprinting Technology: A Precision Approach

Three‐dimensional (3D) bioprinting has matured rapidly over the past decade, combining additive manufacturing with cell biology to fabricate living tissue constructs. The process involves depositing cell‐laden bioinks in a precise, layer‐by‐layer pattern according to a computer‐generated model. For osteochondral repair, bioprinting enables the creation of constructs with regionally varying properties—a stiff, mineralized layer for bone, a softer hydrated layer for cartilage, and an intermediate gradient zone. Different bioprinting modalities are available, each with advantages for different aspects of the construct.

Extrusion‐Based Bioprinting

Extrusion bioprinting uses pneumatic or mechanical pressure to force bioink through a nozzle. It is the most versatile method, capable of depositing high‐viscosity materials like cell‐laden hydrogels, ceramic pastes, and thermoplastic polymers. This method can create the thick, mechanically robust bone layer and the soft cartilage layer in the same print. The main limitation is that shear stress during extrusion can damage cells, though careful optimization of nozzle diameter, pressure, and bioink composition can maintain high viability (typically above 85%).

Inkjet and Laser‐Assisted Bioprinting

Inkjet bioprinting uses thermal or piezoelectric actuation to eject picoliter droplets of bioink. It offers high resolution and can pattern cells very precisely, but is limited to low‐viscosity inks, which may not provide adequate structural support for the bone phase. Laser‐assisted bioprinting (LAB) uses a laser pulse to propel bioink from a donor slide onto a receiving substrate. LAB provides extremely high resolution and single‐cell deposition without nozzle shear stress, but it is slower and more expensive, making it less suitable for large constructs. For osteochondral repair, a hybrid approach is often employed: extrusion for bulk layers and inkjet or LAB for fine patterning of gradients or cell zones.

Bioinks for Osteochondral Bioprinting: Composites and Biomimicry

The choice of bioink is critical because it must support cell viability, provide appropriate mechanical properties, degrade at a controlled rate, and be printable. No single material can fulfill all these requirements for both cartilage and bone. Therefore, researchers use composite bioinks that combine natural polymers (hydrogels) with synthetic polymers and ceramics.

Cartilage‐Phase Bioinks

For the cartilage region, hydrogels such as alginate, gelatin methacryloyl (GelMA), hyaluronic acid, chondroitin sulfate, and agarose are widely used. These materials mimic the high water content and viscoelastic properties of cartilage. GelMA is particularly popular because it supports chondrogenic differentiation and can be crosslinked by UV light to shape after printing. Many formulations include chondroitin sulfate and hyaluronic acid to provide biochemical cues that promote chondrocyte phenotype maintenance. Stem cells (mesenchymal stem cells, MSCs) or primary chondrocytes are suspended in these hydrogels.

Bone‐Phase Bioinks

The bone phase requires stiffness and mineralization. Common strategies include incorporating beta‐tricalcium phosphate (β‐TCP), hydroxyapatite (HA), or calcium phosphate ceramics into hydrogel or polymer blends. Alternatively, bioglass or nanostructured minerals are used. Polycaprolactone (PCL) is a thermoplastic polymer often co‐printed with hydrogel for mechanical reinforcement. For the bone layer, cells such as osteoblasts or MSCs pre‐differentiated toward osteogenic lineage are used.

Gradient and Interface Designs

The interface between cartilage and bone is not a sharp border but a gradual transition from soft hydrated tissue to hard mineralized tissue. Bioprinting can achieve this by varying the composition of bioinks during printing—for example, gradually increasing the concentration of HA or ceramic while decreasing the hydrogel percentage. Another approach is to print multiple layers with intermediate compositions. Some groups print a separate "calcified cartilage" zone using a bioink containing both chondrogenic and osteogenic cues. This gradient is critical for mechanical stress transfer and for recruiting host cells that can integrate.

Integrated Tissue Engineering: From Printing to Maturation

Bioprinting provides the initial scaffold, but the printed construct is not yet functional tissue. Post‐printing maturation is essential. The construct must be cultured in a bioreactor that provides mechanical loading (compression, shear, or perfusion) to stimulate extracellular matrix production. Chondrocytes respond to dynamic compression, while osteoblasts respond to shear from fluid flow. Bioreactors also improve nutrient diffusion into the center of large constructs, which is a major challenge for thick osteochondral units (typically 5–10 mm or more).

In Vitro Maturation and Characterization

After bioprinting, constructs are cultured for 4 to 8 weeks in chondrogenic and osteogenic media. During this period, the cells deposit new matrix, and the construct acquires biomechanical integrity. Histology shows the formation of glycosaminoglycan (GAG) and type II collagen in the cartilage layer, and calcium deposition and osteopontin in the bone layer. The interface zone develops a tidemark‐like structure. Mechanical testing reveals compressive modulus approaching native tissue (0.5–1 MPa for cartilage, 1–5 MPa for bone). Some studies have shown that cell‐free scaffolds impregnated with growth factors (TGF‐β3, BMP‐2) can recruit host cells after implantation, but the current trend favors cellular constructs for faster integration.

In Vivo Studies and Translation Progress

Preclinical studies in small and large animal models have provided promising evidence for bioprinted osteochondral units. In a rabbit model, bioprinted constructs have shown superior integration, subchondral bone restoration, and cartilage quality compared with cell‐free scaffolds or microfracture alone. In sheep, bioprinted constructs with gradient design have maintained their structure for up to 6 months, with tissue ingrowth and no signs of delamination. However, translation to humans has not yet been achieved. The FDA has approved in early‐phase clinical trials only for less complex scaffolds. The main hurdles are scaling up to human joint sizes (which can be 30–50 mm in diameter for the femoral condyle), ensuring consistent quality control, and achieving rapid vascularization in the bone layer, which is critical for resorption of the scaffold and remodeling into living bone.

Current Challenges and Active Research Areas

Despite exceptional progress, several obstacles remain before bioprinted osteochondral units become standard clinical therapy.

Vascularization

The subchondral bone component requires a vascular network to support cell survival and integration with host bone. Bioprinting can include sacrificial channels that are later lined with endothelial cells, or incorporate pro‐angiogenic growth factors. However, creating a functional, patent microvasculature within a thick construct is still an unsolved problem. Many constructs rely on host blood vessel ingrowth after implantation, which is slow and often insufficient for the central regions.

Biomechanical Mismatch

Although the modulus of printed constructs has improved, it is still lower than that of native tissue, especially in the deep bone zone. Over time, the scaffold degrades while new tissue forms, but if the degradation is too fast or too slow, the construct may fail mechanically. The use of reinforced composites (e.g., PCL‐HA) provides initial strength, but these materials may not resorb ideally and could lead to long‐term foreign body reactions.

Scalability and Manufacturing Consistency

Automated bioprinting systems are still largely research tools. Commercial systems must be able to print large constructs quickly while maintaining high cell viability. Sterility, reproducibility, and lot‐to‐lot consistency are challenges. Furthermore, patient‐specific constructs require imaging (MRI or CT) to match the defect geometry, which adds time and cost.

Regulatory Pathway

Bioprinted constructs are classified as combination products (cell + scaffold + device), which fall under complex regulatory pathways. The FDA requires demonstration of safety, efficacy, and manufacturing control. No bioprinted osteochondral product has yet received marketing approval. However, several companies and academic groups are in late preclinical stages or early feasibility studies.

Future Directions: Personalization, Smart Bioinks, and In Situ Bioprinting

Looking ahead, the field is moving toward greater personalization. Advances in medical imaging and artificial intelligence now allow the automatic segmentation of joint defects and generation of printable models. Bioprinting with patient‐derived cells (e.g., autologous MSCs or induced pluripotent stem cells) could eliminate immune rejection. Another frontier is smart bioinks that change properties in response to the local environment (pH, enzyme activity, mechanical load). For example, a bioink could release growth factors only when it senses tissue degradation, promoting on‐demand repair. Moreover, in situ bioprinting—using a portable bioprinter that creates the construct directly inside the joint during arthroscopic surgery—is being explored. This approach avoids the logistical challenges of off‐site manufacturing and could allow immediate implantation. A recent proof‐of‐concept study demonstrated in situ bioprinting of cartilage in a sheep knee using a handheld device.

Conclusion

Bioprinting of osteochondral units holds extraordinary potential to transform the treatment of joint injuries and osteoarthritis. By combining the precision of additive manufacturing with the regenerative potential of living cells, researchers are building integrated constructs that replicate the complex architecture of the native cartilage‐bone interface. While challenges in vascularization, biomechanics, scaling, and regulation remain, the pace of innovation is accelerating. Early preclinical outcomes are encouraging, moving the field closer to clinical reality. For orthopaedic surgeons and patients, bioprinting represents a future where joint restoration is not a patch but a true regeneration of form and function. Continued investment in materials science, bioreactor design, and clinical trials will be essential to translate this technology into standard care.

External References: